Fig. 3From: In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosisDrug release studies of nanocarrier CCG-222740. a Concentration curve of nanocarrier CCG-222740 and empty liposomes over 14 days. b Cumulative drug release of nanocarrier CCG-222740 and empty liposomes over 14 days. Results represent mean ± SEM for three independent experimentsBack to article page